← Leaderboards
Eric Andrew Appel
Stanford University
$5,430,623
Attributed
$7,525,988
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2019–24$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,525,988 · 3
By mechanism
R01$7,074,311 · 2
R56$451,677 · 1
Top collaborators
- Michael R. Farzan6 shared
Most similar at Stanford University
Same institution · by research overlap
- Bruce A. Buckingham$6,830,180
- Laya Ekhlaspour$963,591
- Jimmy Wu$3,083,877
- David Matthew Maahs$18,119,674
- Michael Z. Lin$20,347,995
Others in their field
Other Emerging Leaders on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
- Yunda Huang · Fred Hutchinson Cancer Center$53,780,853
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Kathleen Maletic Neuzil · Emory University$27,014,427
Research focus
Drug KineticsFormulationPreventSide EffectInjectionsProteinsToxic EffectBiological ProductsPersonsArtificial PancreasExcipientsBlood GlucoseHormone SecretionCombined Modality TherapyInsulinDiabetic RatDiabeticEatingBlood Glucose RegulationDiabetes MellitusGastric EmptyingBlindnessGlucoseDiabetes Management
Grant awards (15)
An injectable hydrogel platform for sustained release of eCD4-Ig$793,531
R01 · FY2024 · AI
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes$451,677
R56 · FY2024 · DK · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$837,265
R01 · FY2023 · AI
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes$619,829
R01 · FY2023 · DK · contact PI
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes$121,021
R01 · FY2023 · DK · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$838,771
R01 · FY2022 · AI
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes$555,173
R01 · FY2022 · DK · contact PI
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes$51,177
R01 · FY2022 · DK · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$846,301
R01 · FY2021 · AI
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes$527,003
R01 · FY2021 · DK · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$1
R01 · FY2021 · AI
An injectable hydrogel platform for sustained release of eCD4-Ig$874,862
R01 · FY2020 · AI
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes$465,466
R01 · FY2020 · DK · contact PI
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes$51,445
R01 · FY2020 · DK · contact PI
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes$492,466
R01 · FY2019 · DK · contact PI